About Marker Therapeutics
Press Releases

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022 at 7:00 AM EDT

Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022

Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023

HOUSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

“2022 has already been an exciting year for Marker as we reported encouraging initial results from the six-patient safety lead-in portion of our Phase 2 AML trial—including elimination of MRD in one MRD positive patient—and announced plans for Company-sponsored trials of our second cell therapy product candidate, MT-601, in pancreatic cancer and lymphoma,” said Peter L. Hoang, Marker’s President and Chief Executive Officer. “We also implemented a new MultiTAA-specific T cell therapy manufacturing process, details of which were presented at the 2022 International Society for Cell & Gene Therapy (ISCT) annual meeting. After completing enrollment of the first 20 patients in the Phase 2 AML trial last year, we anticipate reporting topline data from the active disease group in the main phase of the trial next quarter.”


Acute Myeloid Leukemia (MT-401)

  • In February 2022, Marker announced the initial results of the safety lead-in stage of its Company-sponsored Phase 2 AML trial evaluating MT-401, Marker’s lead MultiTAA-specific T cell product candidate. Results from the safety lead-in demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) based on peripheral blood analysis at Week 32 in one MRD positive patient and induced epitope spreading across multiple AML-associated antigens in that patient.
  • Enrollment of the first 20 patients of the main Phase 2 stage of the AML trial was completed in Q4 2021. Topline readout of Group 2 active disease is anticipated in Q2 2022.
  • Marker announced in February 2022 that it is developing MT-401-OTS, a scalable, off-the-shelf product candidate with the potential to match patients to treatment in under three days. Marker’s open Investigational New Drug application (IND) for MT-401 for the treatment of AML includes an off-the-shelf program. The Company is in the process of developing a patient cell bank inventory and expects to dose the first patient with MT-401-OTS 2023.

Additional Clinical Programs (MT-601)

  • In January 2022, Marker announced that the U.S. Food and Drug Administration granted Orphan Drug designation to MT-601 for the treatment of pancreatic cancer.
  • Marker announced in February 2022 that the Company intends to file INDs for MT-601, Marker’s second MultiTAA-specific T cell product candidate, in lymphoma and pancreatic cancer in 2022. The Company expects to initiate these trials in 2023.


  • In April 2022, the Company announced that it entered into a services agreement with Wilson Wolf Manufacturing Corporation. The agreement includes an $8.0 million upfront cash payment by Wilson Wolf to Marker in exchange for services relating to Marker’s expertise in the manufacture of cell therapies. Wilson Wolf has agreed to pay Marker an additional $1.0 million if the certain work, as defined in the services agreement, is completed within one year from the onset of the services agreement.


Cash Position and Guidance: At March 31, 2022, Marker had cash, cash equivalents and restricted cash of $28.8 million.

R&D Expenses: Research and development expenses were $7.0 million for the quarter ended March 31, 2022, compared to $5.6 million for the quarter ended March 31, 2021.

G&A Expenses: General and administrative expenses were $3.7 million for the quarter ended March 31, 2022, compared to $3.1 million for the quarter ended March 31, 2021.

Net Loss: Marker reported a net loss of $9.9 million for the quarter ended March 31, 2022, compared to a net loss of $8.8 million for the quarter ended March 31, 2021.

About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cell therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.

Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401; our ability to use our manufacturing facilities to support clinical and commercial demand; the timing and use of the CPRIT award; and our future operating expenses and capital expenditure requirements. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. Such risks and uncertainties may be amplified by the COVID-19 pandemic and its impact on our business and the global economy. The Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Marker Therapeutics, Inc.
Condensed Consolidated Balance Sheets
    March 31,   December 31,
      2022       2021  
Current assets:        
Cash and cash equivalents   $ 28,637,217     $ 42,351,145  
Restricted cash     181,864       1,146,186  
Prepaid expenses and deposits     2,196,225       2,484,634  
Other receivables     2,185       237  
Total current assets     31,017,491       45,982,202  
Non-current assets:        
Property, plant and equipment, net     10,276,936       10,096,861  
Construction in progress     4,089,135       2,225,610  
Right-of-use assets, net     9,572,572       9,830,461  
Total non-current assets     23,938,643       22,152,932  
Total assets   $ 54,956,134     $ 68,135,134  
Current liabilities:        
Accounts payable and accrued liabilities   $ 7,348,680     $ 11,134,913  
Lease liability     683,969       620,490  
Deferred revenue     181,864       1,146,186  
Total current liabilities     8,214,513       12,901,589  
Non-current liabilities:        
Lease liability, net of current portion     11,035,857       11,247,950  
Total non-current liabilities     11,035,857       11,247,950  
Total liabilities     19,250,370       24,149,539  
Stockholders' equity:        
Preferred stock - $0.001 par value, 5 million shares authorized and 0 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively     -       -  
Common stock, $0.001 par value, 150 million shares authorized, 83.5 million and 83.1 million shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively     83,451       83,079  
Additional paid-in capital     443,651,176       442,020,871  
Accumulated deficit     (408,028,863 )     (398,118,355 )
Total stockholders' equity     35,705,764       43,985,595  
Total liabilities and stockholders' equity   $ 54,956,134     $ 68,135,134  

Marker Therapeutics, Inc.
Condensed Consolidated Statements of Operations
    For the Three Months Ended
    March 31,
      2022       2021  
Grant income   $ 964,322     $ -  
Total revenues     964,322       -  
Operating expenses:        
Research and development   $ 7,026,066     $ 5,643,029  
General and administrative     3,733,001       3,137,958  
Total operating expenses     10,759,067       8,780,987  
Loss from operations     (9,794,745 )     (8,780,987 )
Other income (expenses):        
Arbitration settlement     (118,880 )     -  
Interest income     3,117       1,537  
Net loss   $ (9,910,508 )   $ (8,779,450 )
Net loss per share, basic and diluted   $ (0.12 )   $ (0.16 )
Weighted average number of common shares outstanding, basic and diluted     83,107,649       56,470,247  

Marker Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
    For the Three Months Ended
    March 31,
      2022       2021  
Cash Flows from Operating Activities:        
Net loss   $ (9,910,508 )   $ (8,779,450 )
Reconciliation of net loss to net cash used in operating activities:        
Depreciation and amortization     576,331       502,743  
Stock-based compensation     1,630,677       1,377,038  
Amortization of right-of-use assets     257,889       251,626  
Changes in operating assets and liabilities:        
Prepaid expenses and deposits     288,409       95,000  
Other receivables     (1,948 )     (308 )
Accounts payable and accrued expenses     (3,953,976 )     (1,482,473 )
Deferred revenue     (964,322 )     -  
Lease liability     (148,614 )     (64,329 )
Net cash used in operating activities     (12,226,062 )     (8,100,153 )
Cash Flows from Investing Activities:        
Purchase of property and equipment     (826,583 )     (442,277 )
Cash used for construction in progress     (1,625,605 )     (958,965 )
Net cash used in investing activities     (2,452,188 )     (1,401,242 )
Cash Flows from Financing Activities:        
Proceeds from issuance of common stock, net     -       52,656,588  
Net cash provided by financing activities     -       52,656,588  
Net (decrease) increase in cash, cash equivlants and restricted cash     (14,678,250 )     43,155,193  
Cash, cash equivalents and restricted cash at beginning of the period     43,497,331       21,352,382  
Cash, cash equivalents and restricted cash at end of the period   $ 28,819,081     $ 64,507,575  

Investors and Media Contacts

Marker Therapeutics:

Neda Safarzadeh
Vice President/Head of Investor Relations, PR & Marketing
(713) 400-6451

Solebury Trout:

Amy Bonanno

Primary Logo

Source: Marker Therapeutics